Company news
Tempest Therapeutics, Inc. news in 2024
Tempest Therapeutics, Inc.'s news releases, calls and decks from 2024, newest first.
Tempest Reports Third Quarter 2024 Financial Results and Provides Business Update
November 11, 2024
Tempest Receives FDA Study May Proceed for Pivotal Phase 3 Trial of Amezalpat Combination Therapy for the Treatment of First-Line Hepatocellular Carcinoma
November 11, 2024
Tempest Extends Limited Duration Stockholder Rights Plan
October 9, 2024
Tempest Announces Agreement with Roche to Support Advancement of Amezalpat Combination Therapy into First-Line Hepatocellular Carcinoma Pivotal Trial
October 9, 2024
Tempest Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
September 19, 2024
Tempest Further Strengthens Leadership Team with Appointment of Sheldon Mullins as Vice President, Regulatory Affairs
September 17, 2024
Tempest Announces the Appointment of Troy M. Wagner as Vice President of Quality Assurance
August 20, 2024
Tempest Announces Successful End-of-Phase 2 Meeting with FDA for Amezalpat (TPST-1120) to Treat First-Line Hepatocellular Carcinoma
August 14, 2024
Tempest Reports Second Quarter 2024 Financial Results and Provides Business Update
August 7, 2024
Tempest Unveils New Survival Data for Amezalpat (TPST-1120) in Randomized First-Line HCC Study Demonstrating a Six-Month Improvement over Control Arm
June 19, 2024
Tempest to Report New Data from Global Randomized Combination Study of Amezalpat (TPST-1120) in First-Line Hepatocellular Carcinoma
June 17, 2024
Tempest Reports First Quarter 2024 Financial Results and Provides Business Update
May 8, 2024
Tempest Reports New Preclinical Data for TPST-1120 in RCC at the AACR Annual Meeting
April 8, 2024
Tempest Announces Publication of Positive Data from Phase 1 Trial of TPST-1120 in Patients with Advanced Solid Tumors in Journal of Cancer Research Communications
April 3, 2024
Tempest Reports Year End 2023 Financial Results and Provides Business Update
March 18, 2024
Tempest Announces Upcoming Presentation of Preclinical Data for TPST-1120 in Renal Cell Carcinoma at the AACR Annual Meeting
March 4, 2024